GNF 5

Key Product Details

Product Description

GNF 5 is a selective, non-ATP competitive allosteric inhibitor of Bcr-Abl (IC₅₀ = 220 nM for wild-type Abl). Binds the myristate-binding site of Abl. Acts in combination with nilotinib to inhibit T315I Bcr-Abl in vitro and in vivo. Analog of GNF 2 (Cat. No. 4399). GNF 5 decreases mitochondrial function in lung cancer cells.

External Portal Information

Chemicalprobes.org

is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of GNF 5 is reviewed on the chemical probes website.

Product Specifications for GNF 5

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GNF 5

The following data is based on the product molecular weight 418.37.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.39 mL	11.95 mL	23.90 mL
5 mM	0.48 mL	2.39 mL	4.78 mL
10 mM	0.24 mL	1.20 mL	2.39 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Luttman ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Cell Rep. 2021 PMID: 34706244
• Iacob Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 2011 PMID: 21264348
• Deng Expanding the diversity of allosteric Bcr-Abl inhibitors. J.Med.Chem. 2010 PMID: 20828158
• Zhang Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010 PMID: 20072125

Product Documents for GNF 5